---
schema_version: "secwatch.filing_event.v1"
accession: "0001387131-23-007787"
form_type: "8-K"
ticker: "TNXP"
cik: "0001430306"
company_name: "Tonix Pharmaceuticals Holding Corp."
filed_at: "2023-06-26T23:59:59+00:00"
generated_at: "2026-06-13T17:00:10.887038+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Tonix Pharma acquires two FDA-approved migraine products Zembrace SymTouch and Tosymra for $25M cash plus earn-outs

## Summary
- Upfront $12M at closing, $3M in Mar 2024, ~$10M for inventory; earn-out royalties based on net sales tiers.
- Acquired products generated ~$23M in 2022 sales (Zembrace $19.6M, Tosymra $3.5M); patent protection to 2036/2031.
- Closing expected June 30, 2023; Upsher-Smith provides transition services for up to 9 months post-close.
- Deal builds commercial infrastructure ahead of potential TNX-102 SL fibromyalgia launch; aligns with TNX-1900 chronic migraine program.
- Managed care contracts covering ~200M patients; products bypass GI tract, useful for migraine with nausea.

## SEC filing metadata
- accession: 0001387131-23-007787
- form_type: 8-K
- ticker: TNXP
- cik: 0001430306
- company_name: Tonix Pharmaceuticals Holding Corp.
- filed_at: 2023-06-26T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 1.01, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1430306/000138713123007787/0001387131-23-007787-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1430306/000138713123007787/tnxp_8k-062323.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001387131-23-007787
- JSON: https://secwatch.observer/filing/0001387131-23-007787.json
- Plain text: https://secwatch.observer/filing/0001387131-23-007787.txt

## Key facts
- Material Agreements
  Tonix Pharmaceuticals Holding Corp. entered into Asset Purchase Agreement with Upsher Smith Laboratories, LLC valued at $15 million in cash (Cash Purchase Price) (effective 2023-06-23).
  - Action: entry
  - Agreement: asset purchase
  - Counterparty: Upsher Smith Laboratories, LLC
  - Value: $15 million in cash (Cash Purchase Price)
  - Effective: 2023-06-23
  source text: On June 23, 2023, Tonix Pharmaceuticals Holding Corp, Inc. (the “ Company ”) and its wholly owned subsidiary Tonix Medicines, Inc., a Delaware corporation (“ Acquisition Sub ” and together with the Company, “ Purchaser ”), entered into that certain Asset Purchase Agreement (the “ Asset Purchase Agreement ”) with Upsher Smith Laboratories, LLC, a Minnesota limited liability company (“ Seller ”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1430306/000138713123007787/0001387131-23-007787-index.htm
- Material Agreements
  Tonix Pharmaceuticals Holding Corp. entered into Transition Services Agreement with Upsher Smith Laboratories, LLC valued at base fees equal to $100,000 per month for the first six months, and $150,000 per months for the seve.
  - Action: entry
  - Agreement: asset purchase
  - Counterparty: Upsher Smith Laboratories, LLC
  - Value: base fees equal to $100,000 per month for the first six months, and $150,000 per months for the seve
  source text: In connection with the Asset Purchase and of as the Closing date, Purchaser will enter into a Transition Services Agreement (the “ Transition Services Agreement ”) with Seller.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1430306/000138713123007787/0001387131-23-007787-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.